MedTrace Logo

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

NCT02324803 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2014-12-24

No results posted yet for this study

Summary

assess the activity and toxicity of second-line treatment with pazopanib after failure of first-line sunitinib treatment in patients with clear cell mRCC; to investigate the potential association of DLL4, Notch1, VEGFA, PDGFRB, HIF-1α and HIF-2α with clinical response to pazopanib in mRCC patients.

Conditions

  • Self Efficacy
  • Adverse Drug Event
  • Carcinoma, Renal Cell

Interventions

DRUG

pazopanib

continuous treatment of 800 mg pazopanib once daily until disease progression

Sponsors & Collaborators

  • Southern China Urology Cancer Consortium

    lead OTHER

Principal Investigators

  • Mian Xie · The First Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02324803 on ClinicalTrials.gov